Clinical and Non Clinical Evaluations of repeat administrations of the FAST PV and mGFR Technology

DESCRIPTION provided by applicant Pharmaco Photonics DBA FAST Biomedical proposes a PHASE IIB project to determine the safety and functionality of repeat administration of the FAST PV and mGFR Technology in both non clinical and clinical studies The long term goal of this SBIR project is to test FASTandapos s fluorescent based test in humans and commercializes this product for rapid detection and quantification of glomerular filtration rate GFR and plasma volume PV in patients with acute kidney injury AKI chronic kidney disease CKD and or volume instability AKI remains a vexing clinical problem resulting in unacceptably high patient mortality development of CKD and enhanced progression to end stage renal disease FAST has developed the FAST PV and mGFR Technology a simple blood draw technique for direct measurement of GFR and PV In CKD patients the estimated GFR eGFR method for determining baseline GFR and following disease progression and response to therapy has proved to be a disappointment Having a rapid point of care ability to measure GFR mGFR would greatly improve patient stratification management and evaluation of therapies The Test is intended as an adjunct to current methods utilized to assess renal function This Test has been successfully tested under physiologic and AKI conditions in dogs and in increasing levels of CKD in humans Based upon this success FAST proposes to test the repeated administration of the FAST PV and mGFR Technology TM in repeat dose non clinical studies Phase IIB Specific Aim Based on success of the non clinical studies FAST proposes to test the repeated administration of the FAST PV and mGFR Technology TM in humans Phase IIB Specific Aim for determination of GFR and PV under an FDA Investigational Device Exemption IDE Pilot Human Trial C GFR and PV will be determined in sixteen healthy volunteers receiving either a volume or protein challenge in order to evaluate the testandapos s safety with rapid repeated doses efficacy and repeatability and quantify renal reserve It will also be studied in an additional eight volunteers of varying degrees of kidney function and compared to an iothalamate clearance with both repeated one week later This will allow for the evaluation of safety and efficacy over the spectrum of GFRs seen in kidney disease with repeat doses one week apart and compared to the present day standard This FAST PV and mGFR Technology TM is of major clinical importance in AKI and CKD patients especially in high risk patients where intense surveillance is necessary for early diagnosis stratification by severity and response to therapy Furthermore this new technology for rapid measurement of GFR will for the first time permit early dynamic assessment of kidney function in multiple animal models of human disease thus expanding scientific knowledge regarding the role of kidney function during early disease onset Finally the ability to quantify and follow PV dynamically will greatly aid the critical care physician in many ICU patients PUBLIC HEALTH RELEVANCE Kidney injury whether acute AKI or chronic kidney disease CKD constitutes a life threatening or often debilitating condition as literature demonstrates a higher morbidity and mortality rate among all patients who develop kidney injury compared to those who do not FAST BioMedical has developed a breakthrough kidney function test FAST PV and mGFR Technology TM that provides a clinically meaningful advantage over existing technology by providing an accurate easy and rapid measurement of glomerular filtration rate and plasma volume PV This will aid in diagnosing determining the extent of injury and measuring the response to therapy in both AKI and chronic kidney disease patients It will also allow for accurate adjustment of medications cleared by the kidneys and those potentially toxic to the kidneys Finally it will aid in the management of hemodynamically unstable patients with PV determinations